Vitamin D3 for Life

Live Enlightened

Article

Vitamin D, Inflammation and Anaemia-Related Iron Restriction: Full Study

Previous related pageVitamin D Supplementation and Clinical Iron Markers Across Populations: Study SummaryNext related pageVitamin D, Inflammation and Anaemia-Related Iron Restriction: Study Summary
Study at a glance

How are vitamin D, inflammation and iron availability linked?

This page reviews studies of vitamin D, inflammation and iron availability, mainly in people with inflammatory bowel disease. Inflammation can raise hepcidin, a hormone that reduces iron release from cells. Iron may then be stored in the body but less available for making red blood cells. Vitamin D may influence this process, but it is only one of several factors.

What links did studies in inflammatory bowel disease find?

In children with inflammatory bowel disease, lower vitamin D was associated with higher hepcidin and lower haemoglobin, the oxygen-carrying substance in red blood cells. The relationship remained after researchers accounted for several measured differences, including inflammation. This did not prove that low vitamin D caused anaemia. Adult studies also linked vitamin D measures with iron availability, without establishing cause and effect.

What changed during vitamin D treatment in children?

In one study, 18 newly diagnosed children completed two weeks of vitamin D treatment. Average blood vitamin D rose from about 22.5 to 32.5 ng/mL. Hepcidin and a measured sign of inflammation each fell by about 81%, while ferritin fell by roughly 40%. Other disease treatment and changing inflammation could have contributed. The improvements cannot be explained entirely by vitamin D.

Do these findings prove vitamin D alone corrects anaemia?

Ferritin reflects iron storage but can also rise during inflammation. A fall in ferritin as inflammation improves does not necessarily mean iron has been lost. Blood loss, poor nutrient absorption and other disease effects can also contribute to anaemia. These studies support a relationship between vitamin D and iron control, but do not prove that vitamin D supplements alone corrects inflammatory anaemia.

Read the full article below ↓

Inflammation can create iron restriction even when iron remains present within the body. Cytokine signalling can increase hepcidin, reduce ferroportin-mediated iron export and retain iron inside macrophages and storage compartments. This contributes to the physiology of anaemia of inflammation and creates an important intersection between vitamin D, immunity and iron handling. Human studies in inflammatory bowel disease show that vitamin D status can track with hepcidin and haemoglobin, while intervention data suggest that changing vitamin D status can coincide with substantial changes in hepcidin and inflammatory activity. These findings extend Vitamin D and Iron Metabolism into inflammatory disease without proving that vitamin D is a universal treatment for anaemia. For a shorter version, see Vitamin D, Inflammation and Anaemia-Related Iron Restriction: Study Summary.

Inflammation can make stored iron biologically difficult to access

Inflammatory anaemia differs from simple depletion of iron stores. During inflammatory signalling, hepcidin can rise and reduce ferroportin activity. Iron becomes less available for erythropoiesis because macrophage recycling and intestinal export are constrained. Ferritin may remain normal or rise because ferritin is both an iron-storage protein and an acute-phase reactant.

This makes iron interpretation difficult during chronic inflammatory disease. A high or normal ferritin concentration does not necessarily mean iron delivery to the bone marrow is adequate. Transferrin saturation, soluble transferrin receptor, C-reactive protein and other measures can add context. The wider biological role of inflammatory signalling is explored in Vitamin D and Chronic Inflammation.

Vitamin D enters this system through more than one potential route. VDR signalling can directly suppress HAMP transcription, while vitamin D also interacts with immune-cell biology and inflammatory signalling. These routes can coexist, which makes inflammatory disease a more complex setting than the short-term healthy-adult hepcidin experiments.

Inflammatory bowel disease provides a human model of interacting pathways

Inflammatory bowel disease is useful for studying this relationship because anaemia, iron deficiency, inflammation and vitamin D insufficiency commonly coexist. It also illustrates why association is difficult to interpret: active disease can simultaneously influence diet, absorption, inflammation, iron loss and vitamin D status.

In a paediatric IBD study, approximately half of participants had biochemical evidence of inflammation. Iron deficiency was common, anaemia affected more than one-third of participants, and vitamin D insufficiency was present in most of the cohort. After statistical adjustment for age, sex, body mass index, inflammatory markers, disease diagnosis and duration, vitamin D insufficiency remained associated with higher hepcidin and lower haemoglobin.

Specifically, vitamin D insufficiency was associated with an increase in hepcidin and a reduction in haemoglobin relative to participants with 25(OH)D at or above 30 ng/mL. This does not establish that vitamin D insufficiency caused the anaemia, but the persistence of the association after adjustment suggests that the relationship was not explained solely by the measured inflammatory burden.

The relationship remains entangled with immune physiology

Vitamin D signalling influences several components of immune regulation. It can affect innate antimicrobial programmes, inflammatory transcription and adaptive immune responses. These mechanisms belong within Vitamin D and Immunity and Vitamin D and Immune Modulation, but they do not imply that vitamin D suppresses inflammation indiscriminately.

Hepcidin itself is part of host defence because reducing extracellular iron availability can limit access to iron by pathogens. An inflammatory increase in hepcidin can therefore be physiologically adaptive in the short term even though persistent elevation can impair erythropoiesis. Vitamin D-mediated modification of hepcidin must be understood within that competing immune and iron-regulatory context.

A prospective paediatric study observed large changes after vitamin D treatment

A prospective study of newly diagnosed paediatric IBD patients compared their baseline physiology with healthy controls and followed a subset after vitamin D treatment. Before treatment, children with IBD had higher hepcidin, IL-6, C-reactive protein and platelet counts, while haemoglobin, serum iron and transferrin were lower.

Eighteen patients completed two weeks of vitamin D treatment. Mean 25(OH)D increased from approximately 22.5 to 32.5 ng/mL, a rise of about 40%. Over the same period, hepcidin fell from approximately 33.9 to 6.7 ng/mL, an 81% reduction. C-reactive protein also fell by approximately 81%, and ferritin fell by roughly 40%.

The magnitude is striking, but causal interpretation requires restraint. These were newly diagnosed patients receiving treatment in an active inflammatory disease setting. The observed improvement cannot automatically be attributed entirely to vitamin D because disease treatment and changing inflammatory activity can alter hepcidin, ferritin and iron handling simultaneously.

Ferritin can fall as inflammation improves without representing loss of iron

The decline in ferritin illustrates why iron markers need physiological interpretation. Ferritin can rise during inflammation independently of increased usable iron stores. A falling ferritin concentration during improvement in inflammatory disease can therefore reflect reduced acute-phase signalling rather than deterioration of iron status.

This is one reason that a blood result should not be treated as an isolated physiological truth. The same principle that limits interpretation of vitamin D measurements also applies to iron biomarkers. Biological Noise in Vitamin D Testing addresses the broader problem of treating dynamic measurements as fixed properties.

Adult IBD evidence also links vitamin D with iron availability

Later work in inflammatory bowel disease examined vitamin D metabolites, iron status, hepcidin and intestinal iron-handling biology. Vitamin D sufficiency was associated with higher ferritin and transferrin saturation. Higher ratios of 1,25(OH)₂D to 25(OH)D were associated with lower hepcidin, while increased 1,25(OH)₂D correlated with higher transferrin saturation in Crohn’s disease.

Experimental work accompanying those observations showed that 1,25(OH)₂D could induce expression of ceruloplasmin in intestinal cells. Ceruloplasmin participates in iron oxidation and handling, suggesting that the vitamin D: iron relationship may extend beyond hepcidin alone. The clinical importance of that route remains less established than the hepcidin mechanism.

The distinction between circulating 25(OH)D and active 1,25(OH)₂D again matters. These metabolites answer different physiological questions, which is why Vitamin D Testing: 25-OH-D vs 1,25-OH₂-D is relevant to interpretation of these disease studies.

Inflammatory anaemia is not controlled by vitamin D alone

Inflammatory disease can affect haemoglobin through several routes. Overt or microscopic blood loss can reduce iron stores. Cytokines can increase hepcidin and limit iron release. Reduced appetite or malabsorption can impair nutrient supply. Chronic disease can alter erythropoietin responsiveness. Renal disease adds further disturbances to erythropoiesis and iron regulation.

Vitamin D can intersect with some of these mechanisms, but that does not make vitamin D status the dominant causal variable. A person can have low vitamin D because active inflammatory disease has changed behaviour, diet or absorption. Conversely, correcting vitamin D may change one component of the regulatory network while anaemia persists because another limiting mechanism remains.

This is consistent with the framework of Functional Vitamin D Status: biological response is created by an interacting physiological system rather than inferred from one circulating measurement.

What these studies establish

Human inflammatory-disease evidence supports a relationship among vitamin D status, hepcidin, inflammation and anaemia-related iron restriction. Vitamin D insufficiency can coexist with higher hepcidin and lower haemoglobin, and short prospective treatment studies show that rising vitamin D status can coincide with substantial reductions in hepcidin during improving inflammatory disease.

The evidence does not prove that vitamin D supplementation alone corrects inflammatory anaemia, nor does it justify interpreting ferritin without inflammatory context. The most defensible model is that vitamin D participates in a network containing immune signalling, hepcidin, ferroportin, iron stores and erythropoiesis.

For the broader reconciliation of mechanistic studies with intervention trials that show null or population-dependent effects, see Vitamin D, Hepcidin, Iron Availability and Anaemia: Evidence Synthesis.

Scientific sources

Vitamin D Status Is Associated with Hepcidin and Hemoglobin Concentrations in Children with Inflammatory Bowel Disease. PMID: 28700535.

Vitamin D Decreases Hepcidin and Inflammatory Markers in Newly Diagnosed Inflammatory Bowel Disease Paediatric Patients: A Prospective Study. PMID: 30840757.

Iron Deficiency in Inflammatory Bowel Disease Is Associated With Low Levels of Vitamin D Modulating Serum Hepcidin and Intestinal Ceruloplasmin Expression. PMID: 35029158.

Related reading

Original sources

Source

Iron Deficiency in Inflammatory Bowel Disease Is Associated With Low Levels of Vitamin D Modulating Serum Hepcidin and Intestinal Ceruloplasmin Expression

Iron Deficiency in Inflammatory Bowel Disease Is Associated With Low Levels of Vitamin D Modulating Serum Hepcidin and Intestinal Ceruloplasmin Expression.

Publication details

Iron Deficiency in Inflammatory Bowel Disease Is Associated With Low Levels of Vitamin D Modulating Serum Hepcidin and Intestinal Ceruloplasmin Expression. PMID: 35029158.

Read more →